MedPath

Effect of Mint and Mefnamic Acid on Menstrual Pai

Phase 3
Completed
Conditions
primary dysmenorrhea.
Primary dysmenorrhoea
Registration Number
IRCT201011205206N1
Lead Sponsor
Hamadan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
432
Inclusion Criteria

Inclusion Criteria: a) Primary dysmenorrhea; b) Single; c) 18-25 years old.
Exclusion criteria: a) Contraindication of mint including obstruction of common bile duct, allergy, cholecystitis, chronic liver disease, and gastroesophageal reflux, b) contraindication of mefenamic acid including: allergy, gastritis, gastric ulcer, chronic renal failure, chronic liver disease, anemia, asthma, diabetes mellitus.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Duration of Dysmenorrhea. Timepoint: After taking. Method of measurement: Standard questionnaire (COX).;Severity of Menstrual pain. Timepoint: After taking. Method of measurement: Standard questionnaire of pain violence(vas).;Amount of menstrual bleeding. Timepoint: End of menstrual periods. Method of measurement: Standard questionnaire of Hylgam menstrual bleeding.;Nausea. Timepoint: End of menstrual periods. Method of measurement: Questionnaire.;Vomiting. Timepoint: End of menstrual periods. Method of measurement: Questionnaire.;Diarrhea. Timepoint: End of menstrual periods. Method of measurement: Questionnaire.
Secondary Outcome Measures
NameTimeMethod
Side effects. Timepoint: After taking. Method of measurement: Questionnaire.
© Copyright 2025. All Rights Reserved by MedPath